(Q46455331)

22 December 2017

title

Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema (English)

1 reference

22 December 2017

author

Ardeschir Ghofrani

12

1 reference

22 December 2017

Ralph T Schermuly

15

1 reference

22 December 2017

Ralf P. Brandes

21

1 reference

22 December 2017

Werner Seeger

26

1 reference

22 December 2017

Joan Albert Barberà

28

1 reference

22 December 2017

Jan Grimminger

Jan Grimminger

22

0 references

Norbert Weissmann

Norbert Weissmann

1

0 references

Johannes-Peter Stasch

11

Johannes-Peter Stasch

1 reference

22 December 2017

23

Walter Klepetko

1 reference

22 December 2017

Friedrich Grimminger

27

Friedrich Grimminger

1 reference

22 December 2017

Nirmal Parajuli

4

Nirmal Parajuli

1 reference

22 December 2017

Alexandra Pichl

3

Alexandra Pichl

1 reference

22 December 2017

Peter Jaksch

24

Peter Jaksch

1 reference

22 December 2017

Mariola Bednorz

18

Mariola Bednorz

1 reference

22 December 2017

author name string

Borja Lobo

2

1 reference

22 December 2017

Michael Seimetz

5

1 reference

22 December 2017

Raquel Puig-Pey

6

1 reference

22 December 2017

Elisabet Ferrer

7

1 reference

22 December 2017

Víctor I Peinado

8

1 reference

22 December 2017

David Domínguez-Fandos

9

1 reference

22 December 2017

Athanasios Fysikopoulos

10

1 reference

22 December 2017

Núria Coll-Bonfill

13

1 reference

22 December 2017

Reiner Frey

14

1 reference

22 December 2017

Jéssica García-Lucio

16

1 reference

22 December 2017

Isabel Blanco

17

1 reference

22 December 2017

Olga Tura-Ceide

19

1 reference

22 December 2017

Elsa Tadele

20

1 reference

22 December 2017

Robert Rodriguez-Roisin

25

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 June 2014

1 reference

22 December 2017

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

22 December 2017

volume

189

1 reference

22 December 2017

page(s)

1359-1373

1 reference

22 December 2017

issue

11

1 reference

22 December 2017

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

The nature of small-airway obstruction in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Inflammation of the airways and lung parenchyma in COPD: role of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Pulmonary vascular involvement in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Structure and regulation of soluble guanylate cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Soluble guanylyl cyclase: more secrets revealed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Riociguat for the treatment of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Molecular cloning and expression of a new α&#x2010;subunit of soluble guanylyl cyclase Interchangeability of the α&#x2010;subunits of the enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

A new form of guanylyl cyclase is preferentially expressed in rat kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Reactive oxygen and nitrogen species in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Riociguat for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

A model of tobacco smoke-induced airflow obstruction in the guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Mechanisms of cigarette smoke-induced COPD: insights from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

NO-independent regulatory site on soluble guanylate cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Pulmonary vascular abnormalities in chronic obstructive pulmonary disease undergoing lung transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Nitric oxide in the pathogenesis of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Increased hydrogen peroxide downregulates soluble guanylate cyclase in the lungs of lambs with persistent pulmonary hypertension of the newborn

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Fgf10 is essential for limb and lung formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Fgf10 dosage is critical for the amplification of epithelial cell progenitors and for the formation of multiple mesenchymal lineages during lung development

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Cigarette smoke induces β2-integrin-dependent neutrophil migration across human endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Reduction of ICAM-1 expression by carbon monoxide via soluble guanylate cyclase activation accounts for modulation of neutrophil migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Pulmonary hypertension in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Riociguat for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Tadalafil therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

Effects of cigarette smoke and hypoxia on pulmonary circulation in the guinea pig

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2037OC

10.1164/RCCM.201311-2037OC

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

release_bzw5apxtevb4vaiwe2ewx7reti

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bzw5apxtevb4vaiwe2ewx7reti

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

24738736

1 reference

22 December 2017